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The Danish Renal Biopsy Register. The Danish Renal Biopsy
Register, created in 1985, is a comprehensive national regis-
ter of all renal biopsies performed in Denmark. It includes
light microscopy diagnoses, immunofluorescence information,
disease localization, and clinical information. The number of
registered biopsies has remained constant since inception at
570/year, 200 of which are from renal allografts. Biopsy analysis
is performed in five regional specialist renal pathology depart-
ments, resulting in a high degree of compliance. Diagnosis in-
tercenter reproducibility has been analyzed. The existence of a
unique personal identity number permits easy linkage to other
national databases, including the national population register,
the dialysis and transplantation register, and the cancer regis-
ter. Studies concerning the relationship of glomerulonephritis to
cancer incidence, and the incidence and prognosis of glomeru-
lonephritis and diabetic glomerulopathy have been published.
The database is available for international studies on approval
by the executive chairman.
The Danish Renal Biopsy Register [Dansk Nyrebiopsi
Register (DANYBIR)] was created in 1985 on the initia-
tive of Professors Ejvind Kemp and Steen Olsen. Renal
diseases are rare, with a large number of subclassifica-
tions, and most nephrology centers will only meet a small
number of patients per year with each type. The aim of the
register was to accumulate computer-based comprehen-
sive pathologic and clinical data concerning all renal biop-
sies performed in the kingdom of Denmark. The expected
benefits of the register were (1) to describe the epidemi-
ology of medical renal disease: incidence, prevalence and
trends in epidemiology; (2) by linkage with other regis-
ters, to describe the prognosis, complications, risk factors
for complications, and other clinical features of medical
renal disease; (3) to serve as a source for identifying pa-
tients with rare renal diseases, for clinical investigations;
and (4) in addition to serving as a source for multicenter
investigations, to serve as an internal database for indi-
vidual research programs at each department.
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DEMOGRAPHICS
The kingdom of Denmark has approximately 5.2 mil-
lion inhabitants, a figure which has remained approxi-
mately constant for some years. There are 15 counties,
and specialist nephrology treatment is provided by 15
nephrology departments, four of which are university
departments. Nearly all renal biopsies are performed in
these departments and analyzed in specialist renal pathol-
ogy departments in the four university hospitals [State
University Hospital (Rigshospital), Herlev, Skejby, and
Odense] and the county hospital of Aalborg. The cen-
tralized structure of the Danish health system thus pro-
vides an opportunity for acquiring comprehensive data
with a minimum of bureaucracy. A further advantage is
the existence of a unique personal identity number for
each patient, consisting of 10 digits, the first six being
the birthday, the second a four digit counter, adjusted
such that all women have even numbers, all males odd.
Thus, 2204560236 refers to a woman born on April 22,
1956. This identity number is common to all medical and
social information, as well as all medical databases, al-
lowing easy and unambiguous epidemiologic merging of
databases.
THE STRUCTURE OF THE REGISTER
The database is owned by the involved departments of
pathology. Each department appoints a member of the
committee, five in all, who in turn appoint a chairman. The
chairman has executive power and has the responsibility
for all secretarial work, contact with other authorities,
and compliance with electronic data legal requirements.
Since the necessary computer hardware and software is
readily available at all university departments, and the in-
volved doctors are not recompensed for their services, the
only financial requirement is remuneration for secretarial
assistance amounting to approximately 2000 Euros/year.
The register is financed by private research funds.
Data collection is paper-based. This was the only practi-
cal option at the initiation of the register and no attempts
have up to now been made to transfer data collection to
the Internet. There are several reasons for this. First, the
paper-based system has achieved very high compliance
rates. It was suspected that more advanced technologic
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solutions would reduce the number of biopsies reported
to the register, a suspicion which has been confirmed by
the experience of other national registries. Second, con-
sidering the present low cost of the register, it is unlikely
that any savings in the day-to-day running of the register
would justify the initial outlay in establishing an Internet
database. Third, the Danish Data Protection Law (vide
infra) would require extra software for secure protection
of data sent over the Internet. Finally, the register has
had no ambition of being on-line. Thus, the content of
the database at any time is only reliable up to a year pre-
vious to the present day.
In practice, the pathologist fills in the data form simul-
taneously to the analysis of the renal biopsy. Accumu-
lated forms are mailed to the chairman for entry into the
database.
THE CONTENT OF THE REGISTER
The following information is collected for each biopsy:
(1) personal identity number, pathology department, lo-
cal biopsy identifier, date of biopsy; (2) up to three clini-
cal diseases (e.g., nephrosis, hypertension, Goodpasture’s
syndrome); (3) renal function defined either as normal,
azotemia, or uremia; (4) up to four pathology diagnoses;
for each diagnosis the following is noted [disease lo-
calization (e.g., glomerulus, interstitium, blood vessels)
and name using the SNOMED classification [1]; (5) im-
munofluorescence is performed where practical and rele-
vant (in practice in 78% of cases); the presence of immune
deposition at the following sites is noted (basement mem-
brane, mesangium, tubulus, capillaries, and arteries); and
(6) the existence of electron microscopic analysis, but no
the electron microscopic results.
One disadvantage of the register content is the relative
paucity of clinical data. The inclusion of such information
like blood pressure, degree of proteinuria, renal func-
tion, and serologic disease markers and inflammation pa-
rameters would all have been of considerable value, but
were excluded, again for fear of reducing compliance.
Data concerning the medical treatment of patients were
considered to be of no interest, since nonrandomized re-
sults would be virtually impossible to interpret. Since the
inception of the register then annual number of biop-
sies has remained constant at approximately 570/year, of
which approximately 200/year have been biopsies from
renal allotransplants. Thus, the incidence of native re-
nal biopsy performance is 71/million/year. Most of these
biopsies have been performed for the purpose of diagnos-
ing glomerular disease (47/million/year). This relatively
low figure is mainly due to the generally restrictive atti-
tude of nephrologists to renal biopsy, it being performed
only where there is a clear possibility of therapeutic con-
sequences. Thus, patients with minimal hematuria or pro-
teinuria will often not be investigated invasively.
PROBLEMS WITH THE REGISTER
Complexity versus reliability
As mentioned above, the structure and content of the
register was designed to achieve maximal compliance by
making data entry as easy as possible for the pathologist.
The price of this has been loss of valuable clinical infor-
mation. This balance is a problem facing all researchers in
the creation of clinical databases. Often, databases are es-
tablished in a surge of enthusiasm. The contributors to the
database do not receive renumeration for their work, and
most do not gain personal scientific benefit from the con-
tent. After some time, they can easily come to regard the
database as an onerous “black box,” gradually reducing
compliance. Below a certain limit of comprehensiveness,
the scientific value of the database falls rapidly.
Reproducibility
The value of any multicenter register is critically de-
pendent upon a uniform interpretation of data. This
is especially important in pathology, where diagnoses
often have a subjective element. All registries should
therefore perform, and publish, investigations concern-
ing the intercenter reproducibility of data. This has
been done for DANYBIR [2]. The results showed high
reproducibility for such diagnoses as crescentic, endo-
capillary, and membranous glomerulonephritis, while
agreement on mesangioproliferative and membranopro-
liferative glomerulonephritis was lower. It should, how-
ever, be added that this was a light microscopic study,
and the addition of immunofluorescence and electron
microscopy data would undoubtedly have improved the
figures.
Data protection laws
Medical data contain highly sensitive information re-
quiring the highest degree of protection from unautho-
rized perusal. Previously, this required only a good lock
and key, but since the widespread use of the Internet,
the possibilities for invasion of privacy have increased
dramatically. Many countries have introduced legisla-
tion to specifically address this issue. The Danish Data
Protection Agency (Datatilsynet) requires the following:
(1) central government registration and approval of all
databases; (2) a designated database administrator; (3)
access to the database only by user name and password;
(4) the administrator keeps a log book of all database
access; and (5) data sent over the Internet must be
encrypted.
These necessary measures have increased the adminis-
trative burden associated with maintaining the database.
RESULTS
The register has been the source of a number of epi-
demiologic studies. The database has been linked to the
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Fig. 1. The epidemiology of glomerulonephritis. (Reprinted with per-
mission from [3]).
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Fig. 2. The prognosis of glomerulonephritis. Relative risk compared
to the general population. Symbols are: () patient mortality; ( ) com-
bined patient mortality and renal failure; whiskers, confidence interval
(reprinted with permission from [3]).
National Population Register (containing the births and
deaths of all Danish citizens), the Patient Admission
Register (LPR) (containing the discharge diagnoses of
all in-patient treatments in Denmark), and the Danish
Society of Nephrology Register (containing clinical de-
tails of all patients receiving active treatment for termi-
nal uremia, including dialysis and transplantation). Using
this, reliable information has been published concerning
the epidemiology, clinical complications, and prognosis
of glomerulonephritis [3] (Figs. 1 and 2) and diabetic
nephropathy [4]. Furthermore, linkage with the National
Cancer Register has revealed a generalized increased risk
of cancer for nearly all forms of glomerulonephritis dur-
ing the first 5 years after diagnosis [5] (Tables 1 and 2).
This finding, of considerable scientific and etiologic inter-
est, contrasts to the conventional textbook statement that
only membranous glomerulonephritis is associated with
Table 1. Risk of developing cancer after diagnosis of
glomerulonephritis
Relative risk
Years after biopsy Males Females
0 to 1a 2.4 2.87
1 to 4a 1.97 1.79
≥5 0.88 0.94
aP < 0.05 (adapted with permission from [5]).
Table 2. Glomerular pathology and relative risk of developing cancer
Relative risk
Diagnosis Males Females
Endocapillarya 3.95 2.02
Minor changea 2.37 4.07
Focal segmental sclerosis 2.79 2.63
Extracapillary 1.82 2.13
Membranousa 1.79 1.97
Mesangioproliferativea 1.83 1.75
Unclassifieda 2.08 1.16
Membranoproliferative 1.26 1.59
Sclerosis 1.98 –
aP < 0.05 (adapted with permission from [5]).
increased risk. The study has also identified hemopoietic
tissue as the prime target of increased malignancy. It is
difficult to imagine how this information could have been
obtained without the dedicated work of the contributors
to the register.
THE FUTURE
The Danish Society of Nephrology Register for Ac-
tive Treatment of Terminal Uremia is a publicly financed
national register containing clinical data of all patients
treated for kidney failure. Due to an ongoing coopera-
tion with a computer firm (UNI-C) future compliance
with the latest computer technology and legal obliga-
tions is assured. Plans for an on-line register are afoot.
It would be natural for the DANYBIR to be absorbed
into this Register, and this possibility is currently being
investigated.
Reprint requests to Dr. James Heaf, Graevlingestien 9, 2880
Bagsvaerd, Denmark.
E-mail: heaf@DADLNET.DK
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